Along with this, it should be noted that the use of cell therapy based on dendritic cells is safe; the local and systemic reactions (rash, itching and fever) that have been described are rare, in contrast to those that have been described for other immunotherapy approaches, such as graft-versus-host disease (GVHD) and immunosuppression (with allogeneic bone marrow transplantation), cytokine storm syndrome, neurotoxicity (with CAR T-cell therapy), and autoimmune reactions (with blockade of CTLA-4 or PD-1) [171,172]. Here, CTLA4 is linked to graft versus host disease.